Alice announced that the core product, vometinib mesylate tablets, was recently included in the publication list of proposed breakthrough treatment varieties by the Drug Evaluation Center of the State Drug Administration. The proposed indication is first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor PACC mutations. The publicity period is December 25, 2025 to January 4, 2026.

Alice announced that the core product, vometinib mesylate tablets, was recently included in the publication list of proposed breakthrough treatment varieties by the Drug Evaluation Center of the State Drug Administration. The proposed indication is first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor PACC mutations. The publicity period is December 25, 2025 to January 4, 2026.